



PTO/SB/08B(10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/714,449
Filing Date	November 16, 2000
First Named Inventor	Gabriel Vogeli
Group Art Unit	1646
Examiner Name	J. Murphy
Attorney Docket Number	PHRM0003-101

RECEIVED

MAR 04 2003

TECH CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	American Veterinary Medical Association, <i>Report of the American Veterinary Medical Assoc.</i> ; Panel on Euthanasia, <i>Journal of American Veterinary Medical Assoc.</i> , 1993, 202, 229-249	
	*AB	Ausubel, et al. (Eds.), <i>Current Protocols in Molecular Biology</i> , New York, 1987-1999, John Wiley & Sons	
	*AC	Ausubel, et al. (Eds.), "Protocols in Molecular Biology," <i>John Wiley & Sons</i> , 1994, 6.0.3-6.4.10	
	*AD	Gazit, A., et al., "Tyrophostins I: Synthesis and biological activity of protein tyrosine kinase inhibitors," <i>J. Med. Chem.</i> , 1989, 32, 2344-2352	
	*AE	Gazit, A., et al., "Tyrophostins 3: Structure-activity relationship studies of α -substituted benzyldenemalononitrile 5-S-aryltyrophostins," <i>J. Med. Chem.</i> , 1993, 36, 3556-3564	
	AF	Lehninger, "Chapter 4, The amino acid building blocks of proteins," <i>Biochemistry</i> , 2 nd Ed., 1975, Worth Publishers, Inc., New York, New York, 71-77	
	AG	Lemus, et al., "Studies of extended quinone methides. Synthesis and physical studies of purine-like monofunctional and bifunctional imidazo[4,5-g]quinazoline reductive alkylating agents," <i>J. Org. Chem.</i> , 1989, 54, 3611-3618	
	AH	Morrison, et al., "Genetically engineered antibody molecules," Dixon, F.J., et al., (Eds.), <i>Adv. Immunol.</i> , 1989, 44, 65-92.	
	*AI	Sambrook, et al., <i>Antibodies A Laboratory Manual</i> , 1989, Cold Spring Harbor Laboratory: Cold Spring Harbor, New York	
	AJ	Whiteford, H. A., et al., "Mianserin-Induced Up-Regulation of Serotonin Receptors on Normal Human Platelets <i>in Vivo</i> , <i>Life Sciences</i> , 1993, 53(4), 371-376.	

Examiner
Signature

Date
Considered

11-19-03

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner

¹ Unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.